…engthening surveillance to address these challenges.Conclusions Diphtheria and pertussis are resurging in the Americas. The growing number…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 107 of 2459…topenias, high-titer ANA and anti-dsDNA led to SLE diagnosis so hydroxychloroquine and glucocorticoid were started. In 2014, due to high proteinur…
…Objectives The 2023 EULAR and 2025 ACR SLE recommendations endorse a treat-to-target (T2T) strategy aiming…
…tologic (lymphopenia), and serologic activity (SLEDAI-2K 6–8 on prednisolone 10 mg/day).Results In August 2024, anifrolumab 300 mg IV monthl…
…2% female; 96.0% Caucasian). At enrolment, 88.2% were receiving hydroxychloroquine (n=179). Overweight/obesity prevalence was 60.1%, and 83.3% had…
…esulting in symptom improvement while continuing siltuximab for Castleman disease.Results The patient‘s complex clinical course underlines the ch…
…nd induces NfL release in neuronal cells which is attenuated by anifrolumab. Our findings propose a role for type I IFN in neuronal injury …
…l (66.7%), azathioprine (11%) and tacrolimus (11%)]. 2 received Belimumab monotherapy.Baseline combined SLEDAI was 10.2±3.9 (range 4-16),…
…y/intolerant SLE, OBZ yielded promising responses, including in lupus nephritis, with acceptable safety. These findings support OBZ as a therap…
…cally in hyperlipidemic lupus mice following mPSL pulse.Methods SLE was induced using the TLR7 agonist imiquimod (IMQ) in C.KOR/Stm…
…disease in the peripartum period. Uptake of SLE treatments (eg. hydroxychloroquine), remain suboptimal during pregnancy. We examined medication us…